Structure-based discovery of highly selective phosphodiesterase-9A inhibitors and implications for inhibitor design

Journal of Medicinal Chemistry

Volumn 55, Issue 19, 2012, Pages 8549-8558

  Meng, Fei ^a   Hou, Jing ^a   Shao, Yong Xian ^a   Wu, Pei Ying ^b   Huang, Manna ^a   Zhu, Xinhai ^a   Cai, Yonghong ^a   Li, Zhe ^a   Xu, Jie ^a   Liu, Peiqing ^a   Luo, Hai Bin ^a   Wan, Yiqian ^a   Ke, Hengming ^a,b  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[1 (2 CHLOROPHENYL) 4 HYDROXY 1H PYRAZOLO[3,4 D]PYRIMIDIN 6 YL]AMINO] N (2 METHOXYPHENYL)PROPANAMIDE; 2 [[1 (2 CHLOROPHENYL) 4 HYDROXY 1H PYRAZOLO[3,4 D]PYRIMIDIN 6 YL]AMINO] N (3 METHOXYPHENYL)PROPANAMIDE; 2 [[1 (2 CHLOROPHENYL) 4 HYDROXY 1H PYRAZOLO[3,4 D]PYRIMIDIN 6 YL]AMINO] N (4 ETHOXYPHENYL)PROPANAMIDE; 2 [[1 (2 CHLOROPHENYL) 4 HYDROXY 1H PYRAZOLO[3,4 D]PYRIMIDIN 6 YL]AMINO] N (4 ISOPROPOXYPHENYL)PROPANAMIDE; 2 [[1 (2 CHLOROPHENYL) 4 HYDROXY 1H PYRAZOLO[3,4 D]PYRIMIDIN 6 YL]AMINO] N (4 METHOXYPHENYL)PROPANAMIDE; 2 [[1 (2 CHLOROPHENYL) 4 HYDROXY 1H PYRAZOLO[3,4 D]PYRIMIDIN 6 YL]AMINO] N (TOLYL)PROPANAMIDE; 2 [[1 (2 CHLOROPHENYL) 4 HYDROXY 1H PYRAZOLO[3,4 D]PYRIMIDIN 6 YL]AMINO] N [4 (METHYLTHIO)PHENYL]PROPANAMIDE; 2 [[1 (2 CHLOROPHENYL) 4 HYDROXY 1H PYRAZOLO[3,4 D]PYRIMIDIN 6 YL]AMINO] N PHENYLPROPANAMIDE; 2 [[4 HYDROXY 1 PHENYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 6 YL]AMINO] N (4 METHOXYPHENYL)PROPANAMIDE; ENZYME INHIBITOR; N (4 ETHOXYPHENYL) 2 [[4 HYDROXY 1 PHENYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 6 YL]AMINO] N (4 METHOXYPHENYL)PROPANAMIDE; PHOSPHODIESTERASE; PHOSPHODIESTERASE IX; PHOSPHODIESTERASE IX INHIBITOR; PHOSPHODIESTERASE V; PYRIMIDINONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CATALYSIS; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG SELECTIVITY; HYDROGEN BOND; IC 50; MOLECULAR DOCKING; PROTEIN DOMAIN;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; MOLECULAR DOCKING SIMULATION; PHOSPHODIESTERASE INHIBITORS; PYRAZOLES; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84867344315     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301189c     Document Type: Article

References (46)

1. Antoni, F. Molecular diversity of cyclic AMP signaling Front. Neuroendocrinol. 2000, 21, 103-132
2. De Felice, F. G.; Wasilewska-Sampaio, A. P.; Barbosa, A. C.; Gomes, F. C.; Klein, W. L.; Ferreira, S. T. Cyclic AMP enhancers and Abeta oligomerization blockers as potential therapeutic agents in Alzheimer's disease Curr. Alzheimer Res. 2007, 4, 263-271
3. Jarnaess, E.; Taskén, K. Spatiotemporal control of cAMP signalling processes by anchored signalling complexes Biochem. Soc. Trans. 2007, 35, 931-937
4. O'Neill, J. S.; Maywood, E. S.; Chesham, J. E.; Takahashi, J. S.; Hastings, M. H. cAMP-dependent signaling as a core component of the mammalian circadian pacemaker Science 2008, 320, 949-953
5. Piper, M.; van Horck, F.; Holt, C. The role of cyclic nucleotides in axon guidance Adv. Exp. Med. Biol. 2007, 621, 134-143
6. Zaccolo, M.; Movsesian, M. A. cAMP and cGMP signaling cross-talk: Role of phosphodiesterases and implications for cardiac pathophysiology Circ. Res. 2007, 100, 1569-1578
7. Bender, A. T.; Beavo, J. A. Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use Pharmacol. Rev. 2006, 58, 488-520
8. Omori, K.; Kotera, J. Overview of PDEs and their regulation Circ. Res. 2007, 100, 309-327
9. Conti, M.; Beavo, J. A. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: Essential components in cyclic nucleotide signaling Annu. Rev. Biochem. 2007, 76, 481-511
10. Ke, H.; Wang, H. Crystal structures of phosphodiesterases and implications on substrate specificity and inhibitor selectivity Curr. Top. Med. Chem. 2007, 7, 391-403
11. Rotella, D. P. Phosphodiesterase 5 inhibitors: Current status and potential applications Nat. Rev. Drug Discovery 2002, 1, 674-682
12. Galie, N.; Ghofrani, H. A.; Torbicki, A.; Barst, R. J.; Rubin, L. J. Sildenafil citrate therapy for pulmonary arterial hypertension N. Engl. J. Med. 2005, 353, 2148-2157
13. Schmidt, C. J. Phosphodiesterase inhibitors as potential cognition enhancing agents Curr. Top. Med. Chem. 2010, 10, 222-230
14. Lipworth, B. J. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease Lancet 2005, 365, 167-175
15. Blokland, A.; Schreiber, R.; Prickaerts, J. Improving memory: A role for phosphodiesterases Curr. Pharm. Des. 2006, 12, 2511-2523
16. Menniti, F. S.; Faraci, W. S.; Schmidt, C. J. Phosphodiesterases in the CNS: Targets for drug development Nat. Rev. Drug Discovery 2006, 5, 660-670
17. Houslay, M. D.; Schafer, P.; Zhang, K. Y. Keynote review: Phosphodiesterase-4 as a therapeutic target Drug Discovery Today 2005, 10, 1503-1519
18. Wunder, F.; Tersteegen, A.; Rebmann, A.; Erb, C.; Fahrig, T.; Hendrix, M. Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line Mol. Pharmacol. 2005, 68, 1775-1781
19. van der Staay, F. J.; Rutten, K.; Bärfacker, L.; Devry, J.; Erb, C.; Heckroth, H.; Karthaus, D.; Tersteegen, A.; van Kampen, M.; Blokland, A.; Prickaerts, J.; Reymann, K. G.; Schröder, U. H.; Hendrix, M. The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents Neuropharmacology 2008, 55, 908-918
20. Verhoest, P. R.; Proulx-Lafrance, C.; Corman, M.; Chenard, L.; Helal, C. J.; Hou, X.; Kleiman, R.; Liu, S.; Marr, E.; Menniti, F. S.; Schmidt, C. J.; Vanase-Frawley, M.; Schmidt, A. W.; Williams, R. D.; Nelson, F. R.; Fonseca, K. R.; Liras, S. Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy J. Med. Chem. 2009, 52, 7946-7949
21. Deninno, M. P.; Andrews, M.; Bell, A. S.; Chen, Y.; Eller-Zarbo, C.; Eshelby, N.; Etienne, J. B.; Moore, D. E.; Palmer, M. J.; Visser, M. S.; Yu, L. J.; Zavadoski, W. J.; Michael, G. E. The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents Bioorg. Med. Chem. Lett. 2009, 19, 2537-2541
22. Hutson, P. H.; Finger, E. N.; Magliaro, B. C.; Smith, S. M.; Converso, A.; Sanderson, P. E.; Mullins, D.; Hyde, L. A.; Eschle, B. K.; Turnbull, Z.; Sloan, H.; Guzzi, M.; Zhang, X.; Wang, A.; Rindgen, D.; Mazzola, R.; Vivian, J. A.; Eddins, D.; Uslaner, J. M.; Bednar, R.; Gambone, C.; Le-Mair, W.; Marino, M. J.; Sachs, N.; Xu, G.; Parmentier-Batteur, S. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943(6-[(3S,4S)-4-methyl-1-(pyrimidin-2- ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H- pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents Neuropharmacology 2011, 61, 665-676
23. Vardigan, J. D.; Converso, A.; Hutson, P. H.; Uslaner, J. M. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 attenuates a scopolamine-induced deficit in a novel rodent attention task J. Neurogenet. 2011, 25, 120-126
24. Nagasaki, S.; Nakano, Y.; Masuda, M.; Ono, K.; Miki, Y.; Shibahara, Y.; Sasano, H. Phosphodiesterase type 9 (PDE9) in the human lower urinary tract: An immunohistochemical study BJU Int. 2012, 109, 934-40
25. Liddie, S.; Anderson, K.; Paz, A.; Itzhak, Y. The effect of phosphodiesterase inhibitors on extinction of cocaine-induced conditioned place preference in mice J. Psychopharmacol. 2012, 26, 1375-1382
26. Saravani, R.; Karami-Tehrani, F.; Hashemi, M.; Aghaei, M.; Edalat, R. Inhibition of phosphodiestrase 9 induces cGMP accumulation and apoptosis in human breast cancer cell lines, MCF-7 and MDA-MB-468 Cell Proliferation 2012, 45, 199-206
27. Kroker, K. S.; Rast, G.; Giovannini, R.; Marti, A.; Dorner-Ciossek, C.; Rosenbrock, H. Inhibition of acetylcholinesterase and phosphodiesterase-9A has differential effects on hippocampal early and late LTP Neuropharmacology 2012, 62, 1964-1974
28. Kleiman, R. J.; Chapin, D. S.; Christoffersen, C.; Freeman, J.; Fonseca, K. R.; Geoghegan, K. F.; Grimwood, S.; Guanowsky, V.; Hajós, M.; Harms, J. F.; Helal, C. J.; Hoffmann, W. E.; Kocan, G. P.; Majchrzak, M. J.; McGinnis, D.; McLean, S.; Menniti, F. S.; Nelson, F.; Roof, R.; Schmidt, A. W.; Seymour, P. A.; Stephenson, D. T.; Tingley, F. D.; Vanase-Frawley, M.; Verhoest, P. R.; Schmidt, C. J. Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo J. Pharmacol. Exp. Ther. 2012, 341, 396-409
29. Hanna, C. B.; Yao, S.; Wu, X.; Jensen, J. T. Identification of phosphodiesterase 9A as a cyclic guanosine monophosphate-specific phosphodiesterase in germinal vesicle oocytes: A proposed role in the resumption of meiosis Fertil. Steril. 2012, 98, 487-495
30. Verhoest, P. R.; Fonseca, K. R.; Hou, X.; Proulx-Lafrance, C.; Corman, M.; Helal, C. J.; Claffey, M. M.; Tuttle, J. B.; Coffman, K. J.; Liu, S.; Nelson, F. R.; Kleiman, R. J.; Menniti, F. S.; Schmidt, C. J.; Vanasse-Frawley, M. A.; Liras, S. Design and discovery of 6-[(3 S,4 S)-4-methyl-1-(pyrimidin-2- ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2 H -pyran-4-yl)-1,5-dihydro-4 H -pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943) a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders. J. Med. Chem. 2012, DOI: 10.1021/jm3007799.
31. Huai, Q.; Wang, H.; Zhang, W.; Colman, R.; Robinson, H.; Ke, H. Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine binding Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 9624-9629
32. Wang, H.; Luo, X.; Ye, M.; Hou, J.; Robinson, H.; Ke, H. Insight into binding of phosphodiesterase-9a selective inhibitors by crystal structures and mutagenesis J. Med. Chem. 2010, 53, 1726-1731
33. Hou, J.; Xu, J.; Liu, M.; Zhao, R.; Luo, H.-B.; Ke, H. Structural asymmetry of phosphodiesterase-9, potential protonation of a glutamic acid, and role of the invariant glutamine PLoS ONE 2011, 6, e18092
34. Liu, S.; Mansour, M. N.; Dillman, K. S.; Perez, J. R.; Danley, D. E.; Aeed, P. A.; Simons, S. P.; Lemotte, P. K.; Menniti, F. S. Structural basis for the catalytic mechanism of human phosphodiesterase 9 Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 13309-13314
35. Jain, A. N. Surflex-Dock 2.1: Robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search J. Comput.-Aided. Mol. Des. 2007, 21, 281-306
36. Fang, J. S.; Huang, D.; Zhao, W.; Ge, H.; Luo, H.-B.; Xu, J. A new protocol for predicting novel GSK-3β ATP competitive inhibitors J. Chem. Inf. Model. 2011, 51, 1431-1438
37. Das, J.; Moquin, R. V.; Pitt, S.; Zhang, R.; Shen, D. R.; McIntyre, K. W.; Gillooly, K.; Doweyko, A. M.; Sack, J. S.; Zhang, H. Pyrazolo-pyrimidines: A novel heterocyclic scaffold for potent and selective p38α inhibitors Bioorg. Med. Chem. Lett. 2008, 18, 2652-2657
38. Sykes, B. M.; Atwell, G. J.; Hogg, A.; Wilson, W. R.; O'Connor, C. J.; Denny, W. A. N-Substituted 2-(2,6-Dinitrophenylamino)propanamides: Novel prodrugs that release a primary amine via nitroreduction and intramolecular cyclization J. Med. Chem. 1999, 42, 346-355
39. Wang, H.; Liu, Y.; Huai, Q.; Cai, J.; Zoraghi, R.; Francis, S. H.; Corbin, J. D.; Robinson, H.; Xin, Z.; Lin, G.; Ke, H. Multiple conformations of phosphodiesterase-5: Implications for enzyme function and drug development J. Biol. Chem. 2006, 281, 21469-21479
40. Wang, H.; Liu, Y.; Chen, Y.; Robinson, H.; Ke, H. Multiple elements jointly determine inhibitor selectivity of cyclic nucleotide phosphodiesterases 4 and 7 J. Biol. Chem. 2007, 280, 30949-30955
41. Wang, H.; Yan, Z.; Yang, S.; Cai, J.; Robinson, H.; Ke, H. Kinetic and structural studies of phosphodiesterase-8A and implication on the inhibitor selectivity Biochemistry 2008, 47, 12760-12768
42. Wang, H.; Liu, Y.; Hou, J.; Zheng, M.; Robinson, H.; Ke, H. Structural insight into substrate specificity of phospodiesterase 10 Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 5782-5787
43. Huai, Q.; Wang, H.; Sun, Y.; Kim, H. Y.; Liu, Y.; Ke, H. Three dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity Structure 2003, 11, 865-873
44. Otwinowski, Z.; Minor, W. Processing of X-ray diffraction data collected in oscillation mode Methods Enzymol. 1997, 276, 307-326
45. Jones, T. A.; Zou, J.-Y.; Cowan, S. W.; Kjeldgaard, M. Improved methods for building protein models in electron density maps and the location of errors in these models Acta Crystallogr. 1991, A47, 110-119
46. Brünger, A. T.; Adams, P. D.; Clore, G. M.; DeLano, W. L.; Gros, P.; Grosse-Kunstleve, R. W.; Jiang, J. S.; Kuszewski, J.; Nilges, M.; Pannu, N. S; Read, R. J.; Rice, L. M; Simonson, T.; Warren, G. L. Crystallography and NMR System: A New Software Suite for Macromolecular Structure Determination Acta Crystallogr. 1998, D54, 905-921